Monthly archive | PharmaTutor

24 October 2016

Panbross Pharmaceuticals looking for ASM

A fast growing Kolkata Based Company, with specialized products, having its marketing network in the Eastern part of Country as well as U.P.

Post : ASM - Sales(01 post)

24 October 2016

Nurture consultancy hiring for Sr. Manager - Clinical Research Support in reputed Pharma company

We are hiring for Sr. Manager - Clinical Research Support in reputed Pharma company in Ambernath location

Post: Sr. Manager - Clinical Research Support

24 October 2016

Work as Business Executive at Panbross Pharmaceuticals

A fast growing Kolkata Based Company, with specialized products, having its marketing network in the Eastern part of Country as well as U.P.

Post : Business Executive

24 October 2016

A BRIEF REVIEW ON ION EXCHANGE CHROMATOGRAPHY

{ DOWNLOAD AS PDF }

ABOUT AUHTORS
Jaha Sultana Mohammed
Pelcat Formulation PVT ltd
sohnivya786@gmail.com

ABSTRACT:
Ion exchange chromatography is probably the most powerful and classic type of liquid chromatography. The popularity of ion exchange chromatography has been increased in recent years because this technique allows analysis of wide range of molecules in pharmaceutical, biotechnology, environmental, agricultural and other industries for water purification to separation of various antibiotics from fermentation broths which will enhance the yields and reduce the production time for industrial process. The main objective of this particular study is to develop some understanding for the process of ion exchange and helps to determine whether or not ion exchange will be useful for a particular application. This topic includes background, theory, instrumentation, application which covers both the production of the ion exchange substance, a resin and its operation depending on the condition of matrix during use.

Read more about U.S. FDA Review sBLA for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer

Bristol Meyer Squibb Companyannounced that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA), which seeks to expand the use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) that has progressed on or after platinum-containing therapy. The FDA granted the application priority review and previously granted Opdivo Breakthrough Therapy Designation for mUC in June 2016, reinforcing the need for new treatment approaches in this patient population. The FDA action date is March 2, 2017.

Read more about Qiagen launch QIAscout for single-cell isolation

Qiagen NV, a leading global provider of sample to insight solutions, announced the launch of QIAscout, a novel instrument for isolation of viable single cells from samples to enable cost-efficient, accurate single-cell analysis for next-generation sequencing (NGS), polymerase chain reaction (PCR) and other downstream applications. The QIAscout instrument, the size of a hand-held mobile device, adds to Qiagen’s sample to insight portfolio of solutions for single-cell analysis in research fields such as oncology, immunology, neurobiology and stem-cell biology.

Read more about Gilead presents positive results from three phase 2 studies of GS-4997 in NASH, PAH, DKD

Gilead Sciences, Inc. announced the top-line results from three phase 2 studies of GS-4997 (selonsertib), an investigational inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in nonalcoholic steatohepatitis (NASH), pulmonary arterial hypertension (PAH) and diabetic kidney disease (DKD). GS-4997 demonstrated anti-fibrotic activity in an open-label phase 2 clinical trial that included 72 patients with NASH and moderate to severe (F2-F3) liver fibrosis, who received treatment with GS-4997 (18 mg or 6 mg orally once daily) alone or in combination with simtuzumab (SIM), an investigational antibody directed against lysyl oxidase-like-2 (LOXL2), or SIM alone (125 mg administered via weekly subcutaneous injections) for 24 weeks.

Read more about CEL-SCI Update Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Corporation announced that company received the Partial Clinical Hold letter from the U.S. Food and Drug Administration (FDA). CEL-SCI has started working on a response to the FDA and will work diligently with the FDA to seek to have the partial clinical hold lifted.

23 October 2016

Applications are invited for post of Laboratory Technician and Data Entry Operator under AIIMS and NIPER | walk in

National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. The Government of India has declared NIPER as an 'Institute of National Importance'. It is an autonomous body set up under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The Institute is conceived to provide leadership in pharmaceutical sciences and related areas not only within the country, but also to the countries in South East Asia, South Asia and Africa. NIPER is a member of Association of Indian Universities and Association of Commonwealth Universities.

Applications are invited for one position each of Laboratory Technician and Data Entry Operator under AIIMS and NIPER Collaborative project titled “New Biotherapeutic Approaches to the Treatment of Tuberculosis” funded by DoP, MC&F, New Delhi.

23 October 2016

Opening for Project Fellow as Industry project- BITS Pilani

Applications are invited from suitable candidates for Project Fellow to work on the following project sponsored by an Industry, under the supervision of Dr. Balaji Gopalan, Department of Chemistry, BITS-Pilani, Hyderabad campus.

Post: Project Fellow

Search

October 2016

Panbross Pharmaceuticals looking for ASM

RECOMMENDED POSTS

Subscribe with us

Jobs by Category